Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide earned FDA approval for weight loss in November 2021 under the brand name Wegovy, becoming the first GLP-1 receptor agonist cleared for this indication. This approval followed clinical trials showing an average weight loss of 15% over 68 weeks in patients with obesity or overweight with weight-related conditions. PlexusDx delivers compounded semaglutide injections from licensed 503A pharmacies to all 50 states, offering the same active ingredient without insurance barriers or membership fees.
FDA Approval Timeline for Semaglutide Weight Loss
The FDA granted approval for semaglutide (Wegovy) on November 4, 2021, following a thorough review of the STEP clinical trial program. This landmark decision represented the first GLP-1 receptor agonist approval specifically for chronic weight management in non-diabetic adults. The approval reflected robust evidence that semaglutide could help patients achieve meaningful, sustained weight loss when combined with lifestyle modifications.
Before the weight loss indication, semaglutide had been available since 2017 as Ozempic for type 2 diabetes management. Healthcare providers and patients noted significant weight loss as a side effect, sparking interest in studying semaglutide specifically for obesity treatment. The company invested in dedicated clinical trials to establish efficacy and safety in the weight loss population, ultimately leading to the 2021 FDA approval under the Wegovy brand.
How FDA Approval Changed Access to Semaglutide for Weight Loss
Prior to 2021, patients seeking semaglutide for weight loss faced limited legal options and significant out-of-pocket costs. Many relied on off-label prescriptions of the diabetes formulation (Ozempic), which created supply chain disruptions and made the medication harder to obtain. The FDA approval of Wegovy created a dedicated supply chain and cleared the pathway for broader clinical adoption.
However, even with official approval, access remained limited by high pharmaceutical prices, insurance coverage gaps, and production shortages that persisted for years after launch. Many patients still turned to compounded versions from licensed pharmacies as a more affordable, immediately available alternative. PlexusDx partners with 503A compounding facilities to deliver medically equivalent semaglutide, starting at $149 per month, with no insurance requirement or membership fee.
Why Compounded Semaglutide Offers Real-World Access
Compounded semaglutide from licensed 503A pharmacies contains the same active pharmaceutical ingredient as brand-name Wegovy, manufactured under strict FDA oversight and quality standards. The key difference is cost and availability: compounded versions avoid the manufacturer's premium pricing and do not depend on brand-name supply constraints. PlexusDx sources all compounded medications exclusively from licensed 503A facilities, never from 503B bulk manufacturers, ensuring pharmaceutical-grade purity and potency.
The compounding pathway allows patients to start treatment within days rather than months, avoid insurance prior authorizations, and pay a predictable monthly price regardless of dose adjustments. Your dose may need to go up as your body responds to treatment, but your price won't. PlexusDx offers compounded semaglutide injections starting at $149 per month across three commitment tiers, plus HSA and FSA eligibility for additional savings.
Personalization Beyond FDA Approval: Genetic Testing for GLP-1 Response
While the FDA approval of semaglutide applies broadly to adults with obesity or overweight with weight-related conditions, individual response varies significantly based on genetic factors. Some patients achieve 20%+ weight loss, while others experience more modest results, depending on genetic variations in GLP-1 receptor function, appetite regulation, and energy metabolism. PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway analysis mapping 14 biological pathways, 49 peptides, and 150+ genetic insights to predict your unique response profile.
Key genetic variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 influence how your body processes GLP-1 signals and manages weight. Understanding these predispositions helps PlexusDx providers select the right medication and dosing strategy from the start. The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment, enabling truly personalized therapy rather than one-size-fits-all dosing.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Did the FDA approve Ozempic or Wegovy for weight loss?
The FDA approved semaglutide under the brand name Wegovy specifically for weight loss in November 2021. Ozempic is the diabetes formulation of the same drug, approved in 2017. Many providers prescribe Ozempic off-label for weight loss, but Wegovy is the official weight loss indication. PlexusDx compounded semaglutide delivers the same active ingredient with broader accessibility and lower cost.
How much weight loss can you expect from semaglutide after FDA approval?
The STEP clinical trials supporting FDA approval showed an average weight loss of 15% of body weight over 68 weeks when semaglutide was combined with lifestyle changes. Some patients achieved weight loss exceeding 20%, while others saw more modest results. Genetic factors, dose tolerance, and adherence to diet and exercise all influence individual outcomes, which is why PlexusDx offers genetic testing to predict your personal response profile.
Is compounded semaglutide from PlexusDx as safe as brand-name Wegovy?
Yes. PlexusDx sources compounded semaglutide exclusively from licensed 503A pharmacies, which operate under FDA oversight and pharmaceutical quality standards identical to brand manufacturers. The active ingredient is the same; the difference is cost and availability. Both compounded and brand-name versions carry the same mechanism of action, side effect profile, and clinical efficacy.
Why is compounded semaglutide cheaper than Wegovy if it's the same medication?
Brand-name Wegovy carries manufacturing, marketing, and distribution costs that are reflected in higher retail pricing, often $900–$1,300 per month. Compounding pharmacies produce medications in smaller batches for specific patient populations, avoiding mass-market overhead. PlexusDx compounded semaglutide starts at $149 per month with no insurance requirement, making FDA-approved therapy genuinely affordable.
How does the Precision Peptide Genetic Test predict my response to semaglutide?
The Precision Peptide Genetic Test analyzes genetic variants in your GLP-1 receptor, appetite regulation pathways, and metabolism genes to predict how your body will respond to semaglutide. Specific variants like GLP1R rs6923761 influence receptor sensitivity, while FTO rs9939609 affects baseline weight regulation. This $99 add-on test, available after one month of PlexusDx treatment, helps providers optimize your medication choice and dose from the start.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Mastering Your Ozempic Injection: Why You Can Take Ozempic In Your Thigh (And How)
Where Should I Inject Zepbound for Best Results?